Clinical trial
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal…
NCT00385203 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00385203 |
|---|---|
| Title | The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). |
| Official title | An Open-Label, Phase II Study to Evaluate the Biological Activity of Cediranib (AZD2171) as Measured by [F 18] Fluoro 2 Deoxy D Glucose - Positron Emission Tomography (FDG-PET) Response, in Patients With Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intolerant to Imatinib Mesylate |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas |
| Intervention type | Drug |
| Interventions | AZD2171 |
| Enrollment | 35 |
| Start date | Sep 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Dec 1, 2009 |
| First posted | Oct 6, 2006 |
| Last update posted | Jul 16, 2012 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: